Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Revolution Medicines (RVMD) Revenue (2019 - 2025)

Revolution Medicines has reported Revenue over the past 6 years, most recently at $12.3 million for Q4 2025.

  • Quarterly results put Revenue at $12.3 million for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $830000.0 (changed N/A YoY), and the annual figure for FY2023 was $11.6 million, down 67.27%.
  • Revenue for Q4 2025 was $12.3 million at Revolution Medicines, up from -$11.4 million in the prior quarter.
  • Over the last five years, Revenue for RVMD hit a ceiling of $15.3 million in Q4 2022 and a floor of -$11.4 million in Q3 2025.
  • Median Revenue over the past 4 years was $7.6 million (2022), compared with a mean of $5.9 million.
  • Biggest five-year swings in Revenue: surged 204.81% in 2022 and later crashed 95.16% in 2023.
  • Revolution Medicines' Revenue stood at $9.5 million in 2021, then skyrocketed by 62.05% to $15.3 million in 2022, then crashed by 95.16% to $742000.0 in 2023, then surged by 1552.02% to $12.3 million in 2025.
  • The last three reported values for Revenue were $12.3 million (Q4 2025), -$11.4 million (Q3 2025), and $742000.0 (Q4 2023) per Business Quant data.